NASDAQ:INSY - Insys Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$5.3099 +0.35 (+7.06 %)
(As of 02/19/2019 09:48 AM ET)
Previous Close$4.96
Today's Range$4.98 - $5.37
52-Week Range$3.35 - $11.65
Volume229,047 shs
Average Volume1.05 million shs
Market Capitalization$394.37 million
P/E Ratio-10.84
Dividend YieldN/A
Beta2.3
Insys Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant adult patients; and SYNDROS, an orally administered liquid formulation of dronabinol for the treatment of chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS. It is also developing Cannabidiol Oral Solution, which has completed pediatric study for the treatment of pediatric epilepsy; has completed Phase II study to treat west syndrome; and is in Phase II study for the treatment of childhood absence epilepsy, as well as Buprenorphine Sublingual Spray that has completed Phase III study to treat acute pain. In addition, the company is developing Cannabidiol Oral Solution for the treatment of prader willi; Buprenorphine/Naloxone Sublingual Spray to treat opioid dependence; and Naloxone Nasal Spray for the treatment of opioid antagonist. Insys Therapeutics, Inc. is headquartered in Chandler, Arizona.

Receive INSY News and Ratings via Email

Sign-up to receive the latest news and ratings for INSY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:INSY
Previous SymbolNASDAQ:NEOL
CUSIPN/A
Phone480-500-3127

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$140.69 million
Book Value$0.86 per share

Profitability

Net Income$-228,010,000.00
Net Margins-128.88%

Miscellaneous

Employees343
Market Cap$394.37 million
OptionableOptionable

Insys Therapeutics (NASDAQ:INSY) Frequently Asked Questions

What is Insys Therapeutics' stock symbol?

Insys Therapeutics trades on the NASDAQ under the ticker symbol "INSY."

When did Insys Therapeutics' stock split? How did Insys Therapeutics' stock split work?

Insys Therapeutics shares split on Monday, March 31st 2014. The 3-2 split was announced on Tuesday, March 4th 2014. The newly minted shares were issued to shareholders after the closing bell on Friday, March 28th 2014. An investor that had 100 shares of Insys Therapeutics stock prior to the split would have 150 shares after the split.

How were Insys Therapeutics' earnings last quarter?

Insys Therapeutics Inc (NASDAQ:INSY) announced its earnings results on Wednesday, August, 8th. The specialty pharmaceutical company reported ($0.33) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.16) by $0.17. The specialty pharmaceutical company earned $23.47 million during the quarter, compared to analysts' expectations of $25.91 million. Insys Therapeutics had a negative return on equity of 266.60% and a negative net margin of 128.88%. The business's revenue was down 44.9% on a year-over-year basis. During the same period in the prior year, the business posted $0.03 EPS. View Insys Therapeutics' Earnings History.

When is Insys Therapeutics' next earnings date?

Insys Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 14th 2019. View Earnings Estimates for Insys Therapeutics.

What price target have analysts set for INSY?

6 brokers have issued 1 year target prices for Insys Therapeutics' shares. Their forecasts range from $4.00 to $11.00. On average, they expect Insys Therapeutics' stock price to reach $7.68 in the next twelve months. This suggests a possible upside of 44.6% from the stock's current price. View Analyst Price Targets for Insys Therapeutics.

What is the consensus analysts' recommendation for Insys Therapeutics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insys Therapeutics in the last year. There are currently 1 sell rating, 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Insys Therapeutics.

Has Insys Therapeutics been receiving favorable news coverage?

Press coverage about INSY stock has trended positive on Tuesday, InfoTrie reports. The research firm scores the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Insys Therapeutics earned a media sentiment score of 2.3 on InfoTrie's scale. They also assigned news stories about the specialty pharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the near term.

Are investors shorting Insys Therapeutics?

Insys Therapeutics saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 8,534,908 shares, an increase of 32.1% from the January 15th total of 6,458,929 shares. Based on an average trading volume of 1,072,688 shares, the short-interest ratio is presently 8.0 days. Currently, 31.8% of the shares of the company are short sold. View Insys Therapeutics' Current Options Chain.

Who are some of Insys Therapeutics' key competitors?

Who are Insys Therapeutics' key executives?

Insys Therapeutics' management team includes the folowing people:
  • Mr. Saeed Motahari, CEO, Pres & Director (Age 53)
  • Mr. Andrew G. Long, Chief Financial Officer
  • Mr. Franc Del Fosse, Sr. VP of Corp. Affairs (Age 47)
  • Dr. Danny L. Tuck, Sr. VP of Quality Operations
  • Mr. B. Sanga Emmanuel, VP & Chief Compliance Officer

Who are Insys Therapeutics' major shareholders?

Insys Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (3.61%), ETF Managers Group LLC (1.98%), Millennium Management LLC (0.73%), D. E. Shaw & Co. Inc. (0.69%), Northern Trust Corp (0.48%) and Geode Capital Management LLC (0.43%). Company insiders that own Insys Therapeutics stock include Brian Tambi, John N Kapoor Trust Dated Sept, Rohit Vishnoi, Saeed Motahari and Steven J Meyer. View Institutional Ownership Trends for Insys Therapeutics.

Which institutional investors are selling Insys Therapeutics stock?

INSY stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc. and Northern Trust Corp. View Insider Buying and Selling for Insys Therapeutics.

Which institutional investors are buying Insys Therapeutics stock?

INSY stock was bought by a variety of institutional investors in the last quarter, including ETF Managers Group LLC, D. E. Shaw & Co. Inc., Millennium Management LLC, Squarepoint Ops LLC, Two Sigma Investments LP, Two Sigma Advisers LP, Magnus Financial Group LLC and Rhumbline Advisers. Company insiders that have bought Insys Therapeutics stock in the last two years include John N Kapoor Trust Dated Sept, Rohit Vishnoi, Saeed Motahari and Steven J Meyer. View Insider Buying and Selling for Insys Therapeutics.

How do I buy shares of Insys Therapeutics?

Shares of INSY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Insys Therapeutics' stock price today?

One share of INSY stock can currently be purchased for approximately $5.3099.

How big of a company is Insys Therapeutics?

Insys Therapeutics has a market capitalization of $394.37 million and generates $140.69 million in revenue each year. The specialty pharmaceutical company earns $-228,010,000.00 in net income (profit) each year or ($0.49) on an earnings per share basis. Insys Therapeutics employs 343 workers across the globe.

What is Insys Therapeutics' official website?

The official website for Insys Therapeutics is http://www.insysrx.com.

How can I contact Insys Therapeutics?

Insys Therapeutics' mailing address is 1333 S. Spectrum Blvd Suite 100, Chandler AZ, 85286. The specialty pharmaceutical company can be reached via phone at 480-500-3127 or via email at [email protected]


MarketBeat Community Rating for Insys Therapeutics (NASDAQ INSY)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  378 (Vote Outperform)
Underperform Votes:  287 (Vote Underperform)
Total Votes:  665
MarketBeat's community ratings are surveys of what our community members think about Insys Therapeutics and other stocks. Vote "Outperform" if you believe INSY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INSY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel